Lung Abnormalities at Multimodality Imaging after Radiation Therapy for Non Small Cell Lung Cancer 1

Transcription

1 Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at Chest Imaging Lung Abnormalities at Multimodality Imaging after Radiation Therapy for Non Small Cell Lung Cancer CME Feature See /rg_cme.html LEARNING OBJECTIVES FOR TEST 4 After reading this article and taking the test, the reader will be able to: Recognize the CT features of radiation-induced lung injury at various intervals after 3D CRT and SBRT for non small cell lung cancer. Describe the relation between the CT pattern of radiation-induced lung injury and the radiation portals and doses used. Differentiate radiation-induced lung injury from residual or recurrent lung cancer at PET/ CT after 3D CRT or SBRT. Anna Rita Larici, MD Annemilia del Ciello, MD Fabio Maggi, MD Silvia Immacolata Santoro, MD Bruno Meduri, MD Vincenzo Valentini, MD Alessandro Giordano, MD Lorenzo Bonomo, MD Three-dimensional (3D) conformal radiation therapy (CRT) and stereotactic body radiation therapy (SBRT) are designed to deliver the maximum therapeutic radiation dose to the tumor, allowing improved local disease control, while minimizing irradiation of surrounding normal structures. The complex configuration of the multiple beams that deliver the radiation dose to the tumor in 3D CRT and SBRT produces patterns of lung injury that differ in location and extent from those seen after conventional radiation therapy. Radiation-induced changes in lung tissue after 3D CRT and SBRT occur within the radiation portals. The imaging appearance of irradiated tissues varies according to the time elapsed after the completion of therapy, with acute-phase changes of radiation pneumonitis represented by ground-glass opacities and consolidation and with late-phase changes of radiation fibrosis manifesting as volume loss, consolidation, and traction bronchiectasis. Knowledge of treatment timelines and radiation field locations, as well as familiarity with the full spectrum of possible radiation-induced lung injuries after 3D CRT and SBRT, is important to correctly interpret the abnormalities that may be seen at computed tomography (CT). Differential diagnoses in this context might include infections, lymphangitic carcinomatosis, local recurrence of malignancy, and radiation-induced tumors. The integration of morphologic information obtained at CT with metabolic information obtained at positron emission tomography is helpful in distinguishing radiation-induced parenchymal abnormalities from residual, recurrent, and new cancers. Thus, multimodality follow-up imaging may lead to substantial changes in disease management. RSNA, 2011 radiographics.rsna.org RadioGraphics 2011; 31: Published online /rg Content Codes: 1 From the Department of Bioimaging and Radiological Sciences, Catholic University, A. Gemelli Hospital, Largo A. Gemelli 8, Rome, Italy. Presented as an education exhibit at the 2009 RSNA Annual Meeting. Received April 16, 2010; revision requested July 13 and received September 16; accepted October 19. For this CME activity, the authors, editors, and reviewers have no relevant relationships to disclose. Address correspondence to A.R.L. ( anna.larici@rm.unicatt.it). RSNA, 2011

2 772 May-June 2011 radiographics.rsna.org Introduction Radiation therapy remains a valuable treatment modality for non small cell lung cancer, despite advances in chemotherapy (1,2). Radiation therapy may be used with various goals, depending on the disease stage. Patients with medically nonoperable stage I II disease may be candidates for radiation therapy with curative intent (3). For resected or resectable stage IIIA non small cell lung cancer with mediastinal nodal involvement (N2), radiation therapy is used as an adjuvant treatment to improve local control (4). In locally advanced unresectable stage III non small cell lung cancer (ie, stages IIIA N2 and IIIB), radiation therapy, often combined with chemotherapy, is the primary local treatment, although long-term outcomes are generally poor because of local and systemic recurrences (5). Radiation therapy is also used with palliative intent in patients with locally advanced or metastatic lung cancer, to relieve pain and symptoms and preserve quality of life (6). Evidence suggests that higher doses of radiation improve local tumor control (2,7). Local tumor control is important to prevent metastatic dissemination and prolong survival. Traditional radiation techniques result in the delivery of therapeutic radiation doses to a broad area, beyond the primary tumor margins (8). Because a greater quantity of normal lung tissue is included in the area treated, the risk of side effects increases and the maximum radiation dose that can be used is limited (8,9). In efforts to reduce the toxic effects and improve the results of radiation therapy, innovative techniques such as three-dimensional (3D) conformal radiation therapy (CRT) and stereotactic body radiation therapy (SBRT) were developed over the past decade (10). In both CRT and SBRT, multiple beams are used to generate a dose distribution that conforms tightly to the target volume (8,11). SBRT, in particular, is used to deliver hypofractionated high-dose tumoricidal x- rays to stage I non small cell lung cancer without irradiating regional lymph nodes (12). Both techniques allow delivery of the maximum radiation dose to the entire tumor volume while minimizing the exposure of normal tissues to radiation (8,12). The more recently developed intensity-modulated radiation therapy and four-dimensional radiation therapy techniques have brought further improvements (increased conformality of the external beam to the target, and reduction in errors due to patient positioning and respiration-related motion, respectively) (10). In helical tomotherapy, one offshoot of intensity-modulated radiation therapy, the geometry of a helical CT scanner is integrated with a linear accelerator to deliver highly conformal radiation doses in an intensity-modulated distribution (13). Intensity-modulated and fourdimensional radiation therapies have not yet been shown definitively to improve outcomes (10), and 3D CRT and SBRT are still the most widely used techniques for clinical treatment of non small cell lung cancer. Depending on patient-specific factors, radiation dose, and tumor site, radiation-induced lung injury may occur (14). Two distinct clinical, pathologic, and radiologic phases of radiation-induced lung injury are recognized: an early phase of radiation pneumonitis, which usually occurs between 1 and 6 months after the completion of radiation therapy (11,15 17); and a later phase of chronic radiation fibrosis, which usually occurs between 6 and 12 months after the completion of radiation therapy (8,14,15). Radiologic manifestations of lung injury after conventional radiation therapy (typical manifestations) usually correspond to the margins of the irradiated field. The complex portal configurations in 3D CRT and SBRT result in lung abnormalities that differ from these typical manifestations in regard to their morphologic characteristics, extent, distribution, and location (atypical manifestations) (14,15). The main differential diagnoses include various conditions that may occur in patients treated for lung cancer, such as infections, lymphangitic carcinomatosis, local recurrence of malignancy, and radiation-induced tumors. Awareness of the therapeutic technique and radiation portals used and the associated possible radiologic pattern of radiation-induced lung injury is required to accurately interpret findings of lung abnormalities at follow-up imaging in patients treated with 3D CRT and SBRT. After a brief technical description of 3D radiation therapies, the article surveys the spectrum of lung abnormalities that may be seen at CT after treatment with 3D CRT or SBRT and discusses the role of positron emission tomography (PET) performed with fluorine 18 fluorodeoxyglucose (FDG) in distinguishing between radiation therapy related lung parenchymal abnormalities and residual or recurrent lung cancer. Specific topics discussed include the clinical and pathologic features of radiation-induced lung injury, the CT appearances of 3D CRT- and SBRT-induced lung injury, the differential diagnosis of posttreatment lung injury, and the role of PET/CT. Three-dimensional Radiation Therapies In conventional radiation therapy, the daily radiation dose is delivered to the tumor in two parallel beams with opposed orientations (eg,

3 RG Volume 31 Number 3 Larici et al 773 Figure 1. (a) Three-dimensional CRT planning image shows the orientation of three coplanar radiation beams used to deliver the maximum radiation dose to the right upper lobe tumor and ispilateral hilar lymph nodes. (b d) Axial (b), coronal (c), and sagittal (d) CT images obtained with a mediastinal window show the spatial distribution of isodose curves (colored areas) with respect to the target volume. The tumor (pink lesion) and the region immediately surrounding it (red area) will receive the maximum radiation dose (100% dose). Normal surrounding lung regions will receive radiation doses that decrease with increasing distance from the tumor (yellow = 70% dose, green = 50% dose, light blue = 20% dose, indigo = 10% dose). anteroposterior and posteroanterior beams, with or without oblique angulation), usually totaling 2 Gy per field combination per day (8). Because of the limited beam orientation, relatively large volumes of normal tissues adjacent to the treatment field (including the mediastinum, chest wall, and adjacent lung) often are irradiated. Doses of more than 60 Gy, which are desirable to improve tumor local control, have not been regularly administered with this technique because of the high risk of radiation-induced injury to these surrounding tissues (8,15). In 3D CRT, a 3D image reconstructed from CT data is used to determine the target volume to be irradiated. In lung cancer treatment planning, the target volume generally includes an additional 1- to 2-cm margin around the tumor edge and a 1-cm margin around regional lymph nodes to compensate for respiratory motion and variations in set-up between daily treatment sessions (8,15). A computer planning system designs beam arrangements with various orientations depending on the 3D configuration of the tumor (Fig 1). Generally, multiple coplanar and noncoplanar radiation fields are used. The dose per day (fraction) is usually less than 2 Gy per field combination. This daily dose is administered over 6 to 7 weeks (the conventional fractionation schedule) (8). The

4 774 May-June 2011 radiographics.rsna.org total exposure per fraction is distributed among multiple beams so that normal anatomic structures are exposed to a subtherapeutic dose, while the target volume receives the maximal radiation dose (8). Three-dimensional CRT provides more accurate dose targeting than conventional radiation therapy and can be used to deliver the highest radiation dose to tumors (70 Gy) with relative sparing of normal tissues (18). SBRT is a 3D conformal technique in which a stereotactic body frame is used to allow the delivery of high radiation doses to small, localized tumors (T1 or T2 lesions) with great accuracy (11). In both techniques, multiple coplanar and noncoplanar beams oriented in various directions are used to generate a dose distribution that conforms to the target volume. However, in SBRT, a steeper gradient is generated between the periphery of the planned target volume (high-dose area) and normal adjacent structures (low-dose areas) because the tumors treated with SBRT are smaller than those treated with 3D CRT and the beam focus is therefore more narrowly circumscribed (11,16). Thus, SBRT has a strong antitumoral effect, while minimizing radiation injury to normal tissues. In SBRT for lung cancer, a hypofractionated scheme is typically used to deliver a total dose of Gy, administered in three to five fractions over a period of 1 2 weeks, with a high ablative per-fraction dose (10 20 Gy per fraction) and a resultant reduction in overall treatment time. However, there is no consensus in the literature about the best dose fractionation schedule for SBRT (12). The small size of tumors treated allows the delivery of a larger dose per fraction so that better local tumor control can be achieved (10,12). In particular, SBRT is highly effective in the treatment of nonoperable stage I non small cell lung cancer, with reported local control rates of 80% to 100% (19). Clinical and Pathologic Features of Radiation-induced Lung Injury Radiation-induced lung injury generally manifests with two distinct well-known clinical and pathologic phases: an early phase of transient radiation pneumonitis and a later phase of chronic radiation fibrosis. The reference point for dating lung changes is the time of completion of radiation therapy (8,14,15,20). Radiation pneumonitis induced by 3D CRT or SBRT usually occurs within the first 6 months after completion of treatment, whereas radiation fibrosis typically occurs at 6 12 months after completion of treatment (11,15 17). Signs and symptoms of radiation pneumonitis may include dyspnea, a cough, a low-grade fever, and chest discomfort, all of which may resolve spontaneously over several weeks, whereas the dyspnea and persistent dry cough in radiation fibrosis are progressive and may be accompanied by signs and symptoms of cor pulmonale. However, fibrosis is more often asymptomatic and may be seen at radiologic imaging without any antecedent radiation pneumonitis (19). Clinically significant radiation pneumonitis develops in 13% 37% of patients who undergo 3D CRT with a radical radiation dose (70 Gy) for treatment of lung cancer (18,21). Steroid treatment that is started in early-stage pneumonitis might prevent the subsequent development of pulmonary fibrosis (22). Symptomatic pulmonary disease from toxic effects of SBRT is less common (4%) (11), presumably because a smaller lung volume is exposed to a high dose of radiation (23). In radiation-induced lung injury, as in other forms of diffuse alveolar damage, three sequential pathologic phases are distinguished: an acute exudative phase, an organizing or proliferative phase, and a chronic fibrotic phase. The first two phases correspond to radiation pneumonitis, being characterized by more or less organized infiltration of macrophages, and the third phase corresponds to radiation fibrosis with progressive collagen deposition and fibrotic changes (14,20).

5 RG Volume 31 Number 3 Larici et al 775 Many variables contribute to the toxic effects of radiation on the lungs (14,20,22). These variables include patient-specific factors such as lung performance status, the presence or absence of preexisting lung disease, and the severity of any pulmonary function impairment. In addition, a number of chemotherapeutic agents (eg, actinomycin D, adriamycin, bleomycin, and busulfan) potentiate the effects of radiation. A tumor location near the mediastinum or nerves also may result in more debilitating radiation-induced injuries (21). The use of SBRT to treat centrally located lung tumors should be weighed carefully against the risk of serious complications following the administration of high-dose radiation with a hypofractionated schedule (12). Treatment-related factors that influence the degree of radiation damage to normal tissue include the total radiation dose, fractionation, and dose rate, as well as the irradiated volume and beam arrangement (14,22). The correlation between the radiation dose and the prevalence of radiation damage is not linear, but the latter generally increases above a certain dose threshold. Pulmonary damage rarely occurs after total radiation doses of less than 20 Gy (subcritical doses), whereas it commonly occurs after doses of Gy and almost always occurs after doses of more than 40 Gy (14,24). A more protracted fractionation schedule reduces the biologic effects of radiation on lung tissue (14). Some studies have investigated a hypothetical dose-volume relationship affecting the likelihood of pulmonary injury after 3D CRT and SBRT (9,23). Since the extent of pulmonary injury has not always correlated with the dose distribution (isodose curve), the minimal dose in the area demonstrating pulmonary change has been taken into consideration. It was reported that the minimal dose to the injured lung is related to the percentage lung volume that receives more than 20 Gy (ie, the V20). The higher the V20, the lower the minimal dose at which damage occurs (9,23). According to Graham et al (9), the V20 should be less than 25% to achieve an incidence of radiation pneumonitis estimated at 0% 4%. Akoi et al (23) reported a minimal lung dose (range, Gy; median, 24 Gy) to the area demonstrating pulmonary injury after SBRT. Nevertheless, there is a lack of data regarding the relationship between the probability of severe radiology-induced changes and the dose-volume distribution used in 3D radiation therapy (11). CT Appearances of Radiation-induced Lung Injury Manifestations of radiation-induced changes in the lung after conventional radiation therapy have been well described in the literature by Libshitz et al (25 27) and Ikezoe et al (28,29). These authors classified the CT appearances of radiationinduced lung injury without considering the time interval after the completion of radiation therapy. Nowadays, it is largely accepted that radiationinduced lung changes should be classified radiologically as either early or late phase with regard to the time interval after the end of treatment, because this classification better corresponds to the clinical and pathologic aspects of radiationinduced lung abnormalities (8,14,15,20). Manifestations of radiation-induced lung injury after 3D CRT and SBRT may be similar to those of conventional therapy with regard to the timeline and radiologic findings in early and late phases. Nevertheless, lung abnormalities after SBRT do not usually occur before 2 3 months after completion of therapy, because of the high dose per fraction (11,17). It is well recognized that as the radiation dose per fraction increases, the probability of late phase injury grows (17). Immediately after treatment, tumor shrinkage might be observed on CT scans without any other findings in the surrounding parenchyma. The early phase of radiation pneumonitis (1 6 months after completion of therapy) manifests

6 776 May-June 2011 radiographics.rsna.org Figure 2. (a) Axial CT image shows the target volume for adjuvant radiation therapy in a 72-year-old woman after a left lower lobectomy for squamous cell carcinoma. A total dose of 50 Gy was administered with 3D CRT to the bronchial stump in the left hilar region, the site of neoplastic infiltration. (b) Chest CT scan obtained 8 weeks after completion of CRT shows typical features of radiation pneumonitis: ground-glass opacity and focal consolidation in the posterior portion of the left upper lobe, within the radiation portals; and a linear opacity (arrow) in the anterior portion of the right lung, an orientation corresponding to a radiation field. (c) Chest CT scan obtained 6 months after completion of CRT depicts radiation fibrosis, with sharply marginated homogeneous consolidation, dilatation and distortion of the lingular bronchus of the left upper lobe (arrowheads), and increasing volume loss of the lobe. radiologically as ground-glass opacities, consolidation, or both, usually in the irradiated lung (Figs 2, 3). Occasionally, at the time of radiation pneumonitis, an ipsilateral pleural effusion associated with atelectasis of the lung may develop (15,24). Although the opacities of radiation pneumonitis may resolve gradually over 6 months without radiologic sequelae when the injury to the lung is limited, in cases of more severe changes, a progression to fibrosis usually occurs (20). The late phase of radiation fibrosis (6 12 months after completion of therapy) appears radiologically as a well-defined area of volume loss with a linear scar or consolidation, parenchymal distortion, and traction bronchiectasis that conforms to the treatment portals (Fig 2). Radiation fibrosis may stabilize or may continue to evolve for as long as 24 months. Shrinkage of the region of fibrotic consolidation or a more sharply defined demarcation between normal and irradiated lung parenchyma may occur (Fig 3). Occasionally, these findings are associated with ipsilateral displacement of the mediastinum and adjacent pleural thickening or effusion.

7 RG Volume 31 Number 3 Larici et al 777 Figure 3. Temporal evolution of radiation-induced lung injury in a 58-year-old woman who underwent adjuvant radiation therapy for a recurrent adenocarcinoma after a right lower lobectomy. (a) Axial CT image obtained for therapy planning shows the recurrent tumor (red area) in the posterior portion of the right lung. A total radiation dose of 42 Gy was administered to this target with 3D SBRT. (b) Chest CT scan obtained 8 weeks after completion of therapy shows a diffuse consolidation that completely fills the high-dose area and is larger than and indistinguishable from the site of the initial tumor. This finding represents radiation pneumonitis. (c) Chest CT scan obtained 9 months after completion of therapy demonstrates shrinkage of the consolidation with progression to fibrosis. (d) Integrated PET/CT image obtained 12 months after completion of therapy shows a linear opacity in the irradiated area, with no evidence of FDG uptake, findings indicative of a complete response to treatment. Because 3D CRT and SBRT deliver a focused therapeutic dose to the tumor via multiple beams, the radiation-induced lung alterations seen at CT differ in morphologic characteristics, location, extent, and distribution from those seen after conventional radiation therapy. Therefore, lung injuries from 3D CRT and SBRT techniques have been described as unusual or atypical (15,17). After 3D CRT, radiation pneumonitis may manifest as focal or nodular ground-glass opacity, consolidation, or both, with the findings usually limited to the area immediately surrounding the treated tumor (8,15). Nevertheless, there is evidence in the literature of CT findings of radiation pneumonitis appearing farther from the tumor site, in both lungs, although still delimited by the radiation portals (Fig 4) (15,30). Abnormalities in lung volumes irradiated at doses under 20 Gy also have been observed (30).

8 778 May-June 2011 radiographics.rsna.org Figure 4. Radiation pneumonitis after 3D CRT in a 69-year-old man with a stage IIIB squamous cell carcinoma of the left upper lobe. (a) Axial CT scan shows the tumor before induction chemotherapy. Concomitant chemo- and radiation therapy of the shrunken tumor were subsequently performed. (b) CT image obtained for radiation therapy planning shows the target volume for 3D CRT, which includes the shrunken tumor located at the intersection of three coplanar beams (yellow circle), as well as ipsilateral mediastinal lymph nodes (green cursor). A total dose of 50 Gy was administered. (c, d) Chest CT scans obtained 3 months after completion of CRT show further shrinkage of the tumor with minimal consolidation in the left upper lobe (arrow in c), adjacent to the hilum, and nodular consolidation in the superior segment of the left lower lobe (arrow in d). Note also the slight ground-glass opacities in the posterior segment of the right upper lobe (arrowheads), a region located within the area of low exposure (10% 20% dose) in b. Lung abnormalities after SBRT are not usually seen at sites remote from the target volume (16). Because of the steeper gradient between the periphery of the target volume (high-dose area) and normal adjacent tissue (low-dose area), radiographic changes after SBRT occur within the high-dose region (which encompasses the tumor and a 3D margin of normal tissue) and typically conform to the shape of the tumor (17). CT findings of early radiation pneumonitis after SBRT have been classified, on the basis of the system developed by Ikezoe et al (28,29), into four patterns: (a) diffuse consolidation (Fig 3), (b) diffuse ground-glass opacities, (c) patchy consolidation and ground-glass opacities (Fig 5), and (d) patchy ground-glass opacities (11,17). The findings are

9 RG Volume 31 Number 3 Larici et al 779 Figure 5. Adenocarcinoma of the right lung in a 75-year-old woman who previously underwent a left lower lobectomy with adjuvant radiation therapy for squamous cell carcinoma (same patient as in Fig 2). (a) Axial CT image obtained for planning of SBRT shows the adenocarcinoma (red area) in the middle lobe. (b) Chest CT scan obtained 4 months after completion of SBRT depicts shrinkage of the tumor, with patchy consolidation (arrow) and ground-glass opacities (arrowhead) that do not fill the high-dose area. (c) Chest CT scan obtained 10 months after completion of SBRT demonstrates a rounded opacity with convex margins (arrowhead) but with no air bronchogram within the irradiated region in the middle lobe. (d) Integrated PET/CT image shows high FDG uptake representing increased metabolic activity in the rounded lesion shown in c. This finding was suggestive of recurrent adenocarcinoma, which was confirmed at subsequent biopsy. defined as diffuse or patchy if lung abnormalities completely fill or do not completely fill the highdose region, as previously defined. Radiologic imaging manifestations of radiation fibrosis after both 3D CRT and SBRT have been classified according to one of three patterns described as modified conventional, masslike, or scarlike (8,17). The modified conventional pattern of radiation fibrosis consists of a well-defined consolidation with volume loss and traction bronchiectasis. This pattern is described as modified conventional because it closely resembles the pattern of fibrosis seen after conventional radiation therapy. However, conventional radiation fibrosis generally involves the entirety of irradiated lung tissue, from anterior to posterior pleural surface, whereas modified conventional radiation fibrosis is less extensive (Fig 6) (8).

10 780 May-June 2011 radiographics.rsna.org Figure 6. Modified conventional pattern of radiation fibrosis in a 70-year-old man with adenocarcinoma of the right upper lobe and ipsilateral mediastinal and hilar lymph node involvement treated with neoadjuvant concomitant chemotherapy and 3D CRT at a total dose of 50 Gy. (a) CT image obtained for 3D CRT planning shows the beam configuration needed to deliver the maximum radiation dose to target volumes in the right mediastinum and hilum (red area). (b) CT scan obtained 6 months after therapy shows a well-defined consolidation (white arrow) in the superior segment of the right lower lobe, with associated parenchymal distortion, traction bronchiectasis, and lung volume loss. This consolidation is within a radiation portal that received a 50% dose (green area in a) but does not conform completely to the portal in the anterior portion of the right lung, as demonstrated by the slight opacities in the anterior segment of the right upper lobe (arrowhead). A smaller, dense consolidation (black arrow) is seen adjacent to the right hilum, within the area of maximum dose. Figure 7. Masslike pattern of radiation fibrosis in a 70- year-old man with adenocarcinoma of the right upper lobe and ipsilateral mediastinal and hilar lymph node involvement (same patient as in Fig 6). (a) Coronal CT image obtained for planning of 3D CRT shows the beam configuration used to deliver the maximum dose to the tumor. (b) Coronal chest CT scan obtained 6 months after completion of therapy demonstrates a rounded region of consolidation resembling a lung mass (arrow) with traction bronchiectasis, located within the target area of maximum radiation exposure (red area in a). The region of consolidation is slightly displaced toward the hilum. (c) Coronal CT scan obtained 12 months after completion of therapy shows shrinkage of the consolidation, helping confirm that the cause was radiation-induced fibrosis and not tumor recurrence.

11 RG Volume 31 Number 3 Larici et al 781 Figure 8. Scarlike pattern of radiation fibrosis in a 58-yearold man after neoadjuvant concomitant chemotherapy and radiation therapy at a total dose of 50 Gy for a stage IIIA squamous cell carcinoma of the right upper lobe with middle lobe infiltration. (a) Axial CT image obtained for planning of 3D CRT shows the beam configuration needed to encompass the tumor mass and right inferior paratracheal lymph nodes. (b, c) Axial (b) and sagittal (c) chest CT scans obtained 5 months after the end of therapy demonstrate almost complete resolution of the tumor, with a linear opacity distorting the minor fissure (arrows) but with no other visible lung abnormalities. A right upper and middle lobectomy was successfully performed. When consolidation with traction bronchiectasis is focal and confined to a 2-cm margin around the original tumor (the region corresponding to the maximal isodose curve delivered), the CT appearance is that of a masslike area larger than the original tumor, and this pattern therefore is described as masslike (Fig 7). In the modified conventional and masslike patterns of radiation fibrosis, consolidations may change shape and location during the 1st year of follow-up because fibrosis causes deformity of the lung, with displacement of the region of change toward or away from the hilum (Fig 7) (16,17). The scarlike pattern of post-crt or -SBRT radiation fibrosis consists of a linear opacity less than 1 cm wide that is associated with moderate to severe volume loss and that remains at the tumor site when the primary mass has completely or almost completely resolved (Fig 8). This pat- tern is markedly different from that of conventional radiation fibrosis. The advent of multidetector CT, with its improved spatial and temporal resolution, has facilitated the identification and characterization of radiation-induced lung injuries in routine CT studies performed during follow-up of patients treated for lung cancer. Differential Diagnosis Awareness of the atypical manifestations of radiation-induced lung injury after 3D CRT and SBRT may be useful for avoiding confusion with other diseases that occur in patients who have undergone therapy for lung cancer, such as infections, lymphangitic carcinomatosis, locally recurrent neoplasms, and radiation-induced neoplasms (15). Careful differential diagnosis, especially with regard to the differentiation of evolving radiation fibrosis from recurrent tumors, is important for determining appropriate therapy. Knowledge of the relationships between CT manifestations and times of initiation and completion of radiation therapy, beam arrangements, and radiation dose delivered can be useful and suggestive of the correct diagnosis.

12 782 May-June 2011 radiographics.rsna.org Figure 9. Pulmonary infection in a 67-year-old man who underwent 3D CRT for recurrence of adenocarcinoma in the right upper lobe after initial treatment with a right lower lobectomy. (a) Axial CT image obtained with a mediastinal window for planning of CRT shows the orientation of two coplanar beams needed to deliver the maximum dose to the tumor. (b) Chest CT scan obtained before completion of CRT shows extensive, confluent regions of dense consolidation outside the radiation portals in the right lung. The tumor is not recognizable within the altered region. The volume of the right lung appears greater than in a because of exudate in the alveolar spaces. In the left lung, centrilobular nodules (arrowheads) and more circumscribed regions of consolidation are seen. The radiologic appearance and distribution of abnormalities, along with the acute onset of a fever and cough, allowed a confident diagnosis of infection. In general, in patients who have received a radiation dose of more than 40 Gy over a period of at least 4 weeks for 3D CRT or 1 2 weeks for SBRT, the most likely cause of abnormalities within the radiation portals on radiologic images obtained within 6 months after cessation of radiation therapy is radiation pneumonitis (11,15 17). A review of chest radiographs and CT scans obtained at the initiation of, during, and after therapy may aid in differentiating normal posttherapeutic changes from abnormal ones. The presence of an infection should be considered a possibility if chest CT scans show pulmonary opacities before the completion of therapy or outside the radiation portal or if diffuse or bilateral lung abnormalities are present (Fig 9) (15,20). Other findings that are suggestive of an infection include centrilobular nodules with a tree-in-bud appearance associated with consolidation or cavitation, common features in cases of tuberculosis (31). Sometimes a superimposed infection occurs in an area of radiation-induced lung abnormality, and cavitation may appear (20,26). Since radiation pneumonitis normally follows a more indolent course than infection does, an abrupt onset of lung abnormalities is generally suggestive of infection (unless steroid therapy was recently discontinued, an event that might unmask latent radiation pneumonitis, or chemotherapeutic agents that potentiate radiation effects were used concomitantly), and appropriate diagnostic and therapeutic steps should be initiated (15,32). Lymphangitic carcinomatosis may clinically mimic radiation-induced lung abnormality by causing dyspnea. However, the greater severity and more rapid progression of symptoms in lymphangitic carcinomatosis, along with the identification of specific CT findings such as smooth or nodular interlobular septal thickening, peribronchovascular interstitial thickening, pleural effusion, and mediastinal lymph nodes, often allow a confident diagnosis (Fig 10). Evidence of diffuse lung abnormalities outside the radiation portals, or bilateral distribution of specific CT findings, increases the level of confidence in a diagnosis of lymphangitic carcinomatosis (33). Local tumor recurrences usually manifest within 2 years after treatment, depending on the initial tumor size, stage, histologic type, and treatment (34). It may be difficult to identify a recurrent tumor on CT scans obtained during the evolution of radiation fibrosis, particularly when a masslike pattern of fibrosis develops (8,15).

13 RG Volume 31 Number 3 Larici et al 783 Figure 10. Lymphangitic carcinomatosis in a 59-year-old man after left lower lobectomy and adjuvant concomitant chemo- and radiation therapy for adenocarcinoma. (a) Axial CT image obtained for planning of 3D CRT shows the beam configuration needed to deliver a total dose of 50 Gy to mediastinal lymph nodes. (b) Axial CT scan, obtained to evaluate the cause of progressive dyspnea and cough 4 months after the completion of therapy, shows smooth thickening and nodular thickening of the interlobular septa in both lungs (white arrows), most visibly in the left lung, outside the area that received the maximum dose. Associated nodular thickening of the right fissures (arrowheads) and bilateral pleural effusion are seen. Mild consolidation with traction bronchiectasis (black arrow) in the left hilar region is due to radiation fibrosis. Knowledge of radiation portal distribution and recognition of specific CT findings allowed a confident diagnosis of lymphangitic carcinomatosis, which is associated with a poor prognosis. Parenchymal consolidation with a straight lateral margin and air bronchograms are typical CT features of stable radiation fibrosis. Alteration in the contour and dimensions of the fibrotic area, with the appearance of a homogeneous opacity without air bronchograms and with convex borders in the irradiated lung on CT scans, should arouse the suspicion that a local tumor recurrence is present (Fig 5) (35). In addition, filling-in of bronchi within a region of radiation fibrosis may represent a locally recurrent malignancy or superimposed infection (36). However, in patients who have undergone hypofractionated SBRT, Takeda et al (37) reported that these CT signs are not always indicative of tumor recurrence because the region affected by radiation fibrosis may continue to evolve as long as 2 years after treatment. When other signs of tumor recurrence appear (eg, nodules outside the zone of radiation fibrosis, pleural effusion long after treatment completion, bone destruction, or mediastinal involvement), the diagnosis of local recurrence becomes easier. Radiation is a well-established carcinogen, particularly with regard to the induction of solid tumors (38). It must be assumed that in addition to genetic predisposition and age-related cancer risk, a successful curative radiation therapy of cancer may, in some cases, cause a new second cancer. The risk of developing a second lung cancer after undergoing irradiation of an initial tumor is difficult to assess because of a lack of large-scale studies including long-term survivors (38). An incidence rate of 2.4 per 100 patient-years is reported for second primary cancers among patients who have undergone combined chemo- and radiation therapy for locally advanced non small cell lung cancer, with the most frequent sites of second tumors being the lung, esophagus, and stomach (39). The risk increases significantly with time after treatment, with the median time interval from the beginning of treatment to the diagnosis of the second primary tumor being approximately 9.6 years (95% confidence interval, years). Lung cancer may arise within or at the edge of the irradiated area (39). The appearance of homogeneous consolidation or increased opacity within preexisting and stable lung abnormalities in the irradiated areas over a long interval should arouse the suspicion that a radiation-induced tumor may be present (Fig 11).

14 784 May-June 2011 radiographics.rsna.org

15 RG Volume 31 Number 3 Larici et al 785 Figure 12. Residual adenocarcinoma in a 51-year-old man after neoadjuvant 3D CRT. (a c) Axial CT images obtained for planning of CRT. Lung window views (a at a higher level than b) show two foci of adenocarcinoma in medial (a) and lateral (b) segments of the middle lobe. Mediastinal window view (c) shows involved subcarinal lymph nodes. (d) CT scan obtained 4 months after CRT shows extensive consolidation in the middle and right lower lobes, a typical finding of radiation pneumonitis. Residual tumor foci are obscured. (e) Integrated PET/CT image shows a focus of high FDG uptake (arrow) representing increased metabolic activity in the lateral segment of the middle lobe, at the periphery of the region of radiation pneumonitis, which shows much lower FDG uptake. A right pleural effusion (arrowheads) associated with pneumonitis also is seen. PET/CT allowed accurate identification of residual tumor within the broader region of radiation pneumonitis. Chest CT does not always allow differentiation of residual or recurrent malignancy from radiation-induced lung injury, particularly early in the post radiation therapy period, before the abnormalities have stabilized (Figs 12, 13) (15). Figure 11. (a) Axial chest CT scan obtained in a 70-year-old-man shows an adenocarcinoma of the left lower lobe, which was treated with a left lower lobectomy followed by adjuvant conventional radiation therapy for mediastinal lymph node involvement. (b) CT scan obtained 2 years after therapy shows a band of increased attenuation (arrows) in the upper lobes, near the mediastinum. This finding represents radiation-induced fibrosis. (c) CT scan obtained 7 years after therapy demonstrates a patchy ground-glass opacity (arrowheads) in the anterior segment of the right upper lobe, near the edge of the band of radiation-induced fibrosis. (d) CT scan obtained 9 years after therapy depicts slight enlargement of the region of ground-glass opacity. (e) CT scan obtained 11 years after therapy shows a solid component within the region of ground-glass opacity. This finding aroused suspicion of malignancy and led to a review of all previous CT images. (f) Integrated PET/CT image shows a region of FDG uptake indicative of increased metabolic activity within the solid component of the lesion. A biopsy proved malignancy, and a right upper lobectomy was performed. (g) Photomicrograph (original magnification, 200; hematoxylin-eosin stain) of a histologic slice shows adenocarcinoma with papillary and acinar components.

16 786 May-June 2011 radiographics.rsna.org Figure 13. Recurrent adenocarcinoma in a 68-year-old man. (a) Axial CT image obtained for planning of 3D SBRT shows the beam configuration needed for delivery of a total dose of 50 Gy to an adenocarcinoma of the left upper lobe. (b, c) Axial CT (b) and integrated PET/CT (c) images obtained 6 months after completion of SBRT show a well-defined bandlike consolidation, a finding suggestive of radiation fibrosis, in the left upper lobe, without substantial FDG uptake in c. Note the right fibrothorax (arrowheads in b). (d, e) Axial CT (d) and integrated PET/ CT (e) images obtained 15 months after the completion of SBRT show a slight decrease in the size of the bandlike consolidation, but a focus of increased FDG uptake within the region in e is suggestive of tumor recurrence. Role of PET/CT FDG PET allows the differentiation of metabolically active tumor from inactive fibrosis after radiation therapy and may have a role in the evaluation of patients with radiation-induced lung changes (40 44). Integrated PET/CT appears to provide higher accuracy than that available with CT alone for distinguishing residual or recurrent tumor from lung changes after radiation treatment in patients with non small cell lung cancer (44). Sensitivity of 100% and specificity of 92% were reported with the use of PET/CT to detect residual or recurrent tumor, in comparison with sensitivity of 71% and specificity of 95% with the use of CT alone (42,44). PET/CT may allow detection of a recurrent tumor even before it is manifested clinically (44). However, PET has demonstrated a lower specificity in this setting,

17 RG Volume 31 Number 3 Larici et al 787 Figure 14. Change in the intensity of FDG uptake over time in radiation-induced abnormalities (same patient as in Fig 2). (a) Integrated PET/CT image obtained 3 months after the completion of adjuvant radiation therapy shows intense FDG uptake in a region of consolidation in the posterior portion of the left upper lobe. This finding is common in the early phase of radiation-induced pneumonitis. (b, c) Integrated PET/CT images obtained 10 (b) and 15 (c) months after the completion of radiation therapy demonstrate progressive shrinkage of the consolidation, along with a gradual decrease in the intensity of FDG uptake. one of its limitations being the frequent falsepositive uptake of FDG soon after completion of radiation therapy. Because radiation pneumonitis may lead to FDG uptake that mimics recurrent disease, PET should not be performed until at least 3 months after the completion of radiation therapy, to reduce the likelihood of false-positive results (Fig 14) (15). Persistent uptake associated with radiation pneumonitis occasionally lasts for 15 months after the end of therapy, and a biopsy may be necessary in such cases. In this context, the evaluation of sequential and semiquantitative PET scans and the calculation of standardized uptake values could provide additional information useful for distinguishing between the inflammatory effects of radiation and the recurrence of a tumor. However, the standardized uptake value is affected by a number of variables (eg, plasma glucose levels, tumor size, camera image resolution) (43), and an absolute value that allows differentiation between tumor recurrence and radiationinduced inflammatory changes has not been proved. In our experience, PET/CT is accurate and reliable for this purpose if performed when there is clinical or radiologic evidence suggestive of recurrence (Fig 5). In that context, increased FDG uptake in lesions is more likely to be indicative of residual or recurrent lung cancer, and additional diagnostic and interventional procedures (bronchoscopy, percutaneous needle-aspiration biopsy, open lung biopsy, thoracentesis) then are required. Because of the high negative predictive value of FDG PET, a finding of little or no FDG uptake is considered a definitive indication that no recurrent lung cancer is present and that CT follow-up alone is sufficient. Summary The appearance and evolution of lung abnormalities resulting from 3D CRT or SBRT for non small cell lung cancer differ from the appearance and evolution of lung abnormalities induced by conventional radiation therapy. Since 3D CRT and SBRT are commonly used to treat lung cancer, knowledge of the full spectrum of CT manifestations that may occur after these therapies, especially in relation to the locations of radiation portals and time intervals from the completion of treatment, is useful for avoiding diagnostic errors. Further, PET/CT can help differentiate between radiation-induced lung abnormalities and residual or recurrent lung cancer. Thus, multimodality imaging after radiation therapy for lung cancer can provide important guidance for patient care. Acknowledgments. We thank Basilio Angrisani, MD, and Guido Rindi, MD, for providing the pathologic diagnoses. We also thank Andrea Caulo, MD, for his help in preparing the figures.

18 788 May-June 2011 radiographics.rsna.org References 1. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17(9): Rosenzweig KE, Amols H, Ling CC. New radiotherapy technologies. Semin Surg Oncol 2003;21 (3): Dosoretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992;24(1): PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005(2):CD Komaki R, Cox JD, Hartz AJ, et al. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 1985;8(5): Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008;26(24): Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol 1996;6(2): Koenig TR, Munden RF, Erasmus JJ, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol 2002;178(6): Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45(2): Haasbeek CJ, Slotman BJ, Senan S. Radiotherapy for lung cancer: clinical impact of recent technical advances. Lung Cancer 2009;64(1): Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010;69(1): Ball D. Stereotactic radiotherapy for nonsmall cell lung cancer. Curr Opin Pulm Med 2008;14(4): Park HJ, Kim KJ, Park SH, Kay CS, Oh JS. Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy. AJR Am J Roentgenol 2009;193(3):W209 W Park KJ, Chung JY, Chun MS, Suh JH. Radiationinduced lung disease and the impact of radiation methods on imaging features. RadioGraphics 2000; 20(1): Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. RadioGraphics 2004; 24(4): ; discussion Takeda T, Takeda A, Kunieda E, et al. Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol 2004;182(5): Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol 2009; Nov 30. [Epub ahead of print] 18. Armstrong J, McGibney C. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. Radiother Oncol 2000;56(2): Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94(1): Davis SD, Yankelevitz DF, Henschke CI. Radiation effects on the lung: clinical features, pathology, and imaging findings. AJR Am J Roentgenol 1992;159 (6): Rodrigues G, Lock M, D Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer: a systematic review. Radiother Oncol 2004;71(2):

19 RG Volume 31 Number 3 Larici et al López Rodríguez M, Cerezo Padellano L. Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol 2007;9(8): Aoki T, Nagata Y, Negoro Y, et al. Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 2004;230(1): Libshitz HI, Southard ME. Complications of radiation therapy: the thorax. Semin Roentgenol 1974; 9(1): Libshitz HI. Radiation changes in the lung. Semin Roentgenol 1993;28(4): Libshitz HI, DuBrow RA, Loyer EM, Charnsangavej C. Radiation change in normal organs: an overview of body imaging. Eur Radiol 1996;6(6): Libshitz HI, Shuman LS. Radiation-induced pulmonary change: CT findings. J Comput Assist Tomogr 1984;8(1): Ikezoe J, Morimoto S, Takashima S, Takeuchi N, Arisawa J, Kozuka T. Acute radiation-induced pulmonary injury: computed tomography evaluation. Semin Ultrasound CT MR 1990;11(5): Ikezoe J, Takashima S, Morimoto S, et al. CT appearance of acute radiation-induced injury in the lung. AJR Am J Roentgenol 1988;150(4): Tada T, Minakuchi K, Matsui K, Kawase I, Fukuda H, Nakajima T. Radiation pneumonitis following multi-field radiation therapy. Radiat Med 2000;18 (1): Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis: CT findings early active disease and sequential change with antituberculous therapy. Radiology 1993;186(3): Salinas FV, Winterbauer RH. Radiation pneumonitis: a mimic of infectious pneumonitis. Semin Respir Infect 1995;10(3): Webb WR, Müller N, Naidich DP. High-resolution CT of the lung. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009; 64(3): Bourgouin P, Cousineau G, Lemire P, Delvecchio P, Hébert G. Differentiation of radiation-induced fibrosis from recurrent pulmonary neoplasm by CT. Can Assoc Radiol J 1987;38(1): Libshitz HI, Sheppard DG. Filling in of radiation therapy-induced bronchiectatic change: a reliable sign of locally recurrent lung cancer. Radiology 1999;210(1): Takeda A, Kunieda E, Takeda T, et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008;70(4): Trott KR. Second cancers after radiation therapy. In: Joiner M, van der Kogel A, eds. Basic clinical radiobiology. 4th ed. London, England: Hodder Arnold, 2009; Takigawa N, Kiura K, Segawa Y, et al. Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006;95(9): Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003;23(2): Erasmus JJ, McAdams HP, Patz EF Jr, Goodman PC, Coleman RE. Thoracic FDG PET: state of the art. RadioGraphics 1998;18(1): Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. RadioGraphics 1992;12(2): Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36(5): Bury T, Corhay JL, Duysinx B, et al. Value of FDG- PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14(6): This article meets the criteria for 1.0 AMA PRA Category 1 Credit TM. See